K. Schenck

发表

Pharmacological Characterization of the Competitive GLUK5 Receptor Antagonist Decahydroisoquinoline LY466195 in Vitro and in Vivo

David Bleakman, Kirk W. Johnson, Andrew Alt, 2006, Journal of Pharmacology and Experimental Therapeutics.

5-Hydroxytryptamine(1F) receptors do not participate in vasoconstriction: lack of vasoconstriction to LY344864, a selective serotonin(1F) receptor agonist in rabbit saphenous vein.

M. Cohen, K. Schenck, Marlene L. Cohen, 1999, The Journal of pharmacology and experimental therapeutics.

Contractile responses to sumatriptan and ergotamine in the rabbit saphenous vein: effect of selective 5‐HT1F receptor agonists and PGF2α

M. Cohen, Marlene L. Cohen, K. Schenck, 2000, British journal of pharmacology.

In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides.

M. Cohen, R. Kauffman, K. Schenck, 1987, The Journal of pharmacology and experimental therapeutics.

Serotonin-induced contraction in canine coronary artery and saphenous vein: role of a 5-HT1D-like receptor.

M. Cohen, M. Baez, K. Schenck, 1994, Life Science.

Sumatriptan and 5-benzyloxytryptamine: contractility of two 5-HT1D receptor ligands in canine saphenous veins.

D. Robertson, M. Cohen, K. Schenck, 1992, European journal of pharmacology.

Role of 5-HT2 receptors in serotonin-induced contractions of nonvascular smooth muscle.

M. Cohen, K. Schenck, W. Colbert, 1985, The Journal of pharmacology and experimental therapeutics.

5-Hydroxytryptamine1B Receptor-Mediated Contraction of Rabbit Saphenous Vein and Basilar Artery: Role of Vascular Endothelium

L. Nisenbaum, Marlene L. Cohen, K. Schenck, 2004, Journal of Pharmacology and Experimental Therapeutics.

Amplification of sumatriptan-induced contraction in rabbit saphenous vein but not in basilar artery.

Marlene L. Cohen, K. Schenck, A. Bhattacharya, 2003, American journal of physiology. Heart and circulatory physiology.

Novel potent 5-HT(1F) receptor agonists: structure-activity studies of a series of substituted N-[3-(1-methyl-4-piperidinyl)-1H-pyrrolo[3,2-b]pyridin-5-yl]amides.

Kirk W. Johnson, T. Branchek, J. Zgombick, 2003, Journal of medicinal chemistry.

Synthesis and biochemical evaluation of tritium-labeled 1-methyl-N-(8-methyl-8-azabicyclo[3.2.1]oct-3-yl)-1H-indazole-3-carboxa mide, a useful radioligand for 5HT3 receptors.

D. Wong, D. Robertson, L. R. Reid, 1990, Journal of medicinal chemistry.

Potent, selective tetrahydro-beta-carboline antagonists of the serotonin 2B (5HT2B) contractile receptor in the rat stomach fundus.

D. Nelson, J. Audia, M. Cohen, 1996, Journal of medicinal chemistry.

N-[3-(2-Dimethylaminoethyl)-2-methyl-1H- indol-5-yl]-4-fluorobenzamide: a potent, selective, and orally active 5-HT(1F) receptor agonist potentially useful for migraine therapy.

J. Zgombick, D. Nelson, J. Audia, 2001, Journal of medicinal chemistry.

In vitro activity of LY393558, an inhibitor of the 5-hydroxytryptamine transporter with 5-HT(1B/1D/2) receptor antagonist properties.

J. Boot, D. Nelson, M. Cohen, 2001, European journal of pharmacology.

Effects of Pinacidil on Serotonin‐Induced Contractions and Cyclic Nucleotide Levels in Isolated Rat Aortae: Comparison with Nitroglycerin, Minoxidil, and Hydralazine

M. Cohen, R. Kauffman, K. Schenck, 1986, Journal of cardiovascular pharmacology.

Potent antagonism of 5-HT(3) and 5-HT(6) receptors by olanzapine.

F. Bymaster, J. Kennedy, M. Cohen, 2001, European journal of pharmacology.

5-Hydroxytryptamine(1A) receptor activation enhances norepinephrine release from nerves in the rabbit saphenous vein.

M. Cohen, K. Schenck, S. H. Hemrick-Luecke, 1999, The Journal of pharmacology and experimental therapeutics.

In vitro receptor specificity of the 5HT1A selective phenylpiperazine, LY165163.

M. Cohen, K. Schenck, N. Mason, 1986, Life sciences.

PHOSPHOLIPID METABOLISM IN SUBACUTE SCLEROSING PANENCEPHALITIS : ACTIVITY OF BRAIN PHOSPHOLIPASE A2 TOWARDS SPECIFICALLY LABELLED 1,2‐DIACYL‐, 1‐ALK‐1′‐ENYL‐2‐ACYL‐ AND 1‐ALKYL‐2‐ACYL‐sn‐GLYCERO‐3‐PHOSPHORYLCHOLINE

H. Woelk, K. Schenck, U. Jakumeit-Morgott, 1976, Journal of neurochemistry.

Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.

D. Nelson, J. Audia, M. Cohen, 1993, Molecular pharmacology.

Selective desensitization of 5-hydroxytryptamine 2A receptor mediated contraction in guinea pig trachea.

M. Cohen, S. Watts, K. Schenck, 1994, Canadian journal of physiology and pharmacology.

Is the "atypical" beta-receptor in the rat stomach fundus the rat beta 3 receptor?

J. Granneman, M. Cohen, A. Palkowitz, 1995, Journal of Pharmacology and Experimental Therapeutics.

Effect of nitrendipine, diltiazem, trifluoperazine and pimozide on serotonin2 (5-HT2) receptor activation in the rat uterus and jugular vein.

M. Cohen, K. Schenck, N. Mason, 1986, The Journal of pharmacology and experimental therapeutics.

Atriopeptin II: differential sensitivity of arteries and veins from the rat.

M. Cohen, K. Schenck, 1985, European journal of pharmacology.

Relationship between 5-HT2A receptor mRNA density and contractility in trachea and aorta from guinea pig and rat.

L. Mercurio, M. Cohen, M. Baez, 1994, Life Science.

Effect of LY53857, a selective 5HT2 receptor antagonist, on 5HT-induced increases in cutaneous vascular permeability in rats.

M. Cohen, K. Schenck, 1989, Life sciences.

Tissue angiotensin converting enzyme inhibition as an index of the disposition of enalapril (MK-421) and metabolite MK-422.

M. Cohen, K. Schenck, K. Kurz, 1983, The Journal of pharmacology and experimental therapeutics.

DOI and alpha-methylserotonin: comparative vascular and nonvascular smooth muscle effects and central 5-hydroxytryptamine2 receptor affinities.

D. Robertson, D. Nelson, M. Cohen, 1993, Journal of Pharmacology and Experimental Therapeutics.

2,3-Dialkyl(dimethylamino)indoles: interaction with 5HT1, 5HT2, and rat stomach fundal serotonin receptors.

M. Cohen, K. Schenck, L. Wittenauer, 1986, Journal of medicinal chemistry.